Skip to main content
Premium Trial:

Request an Annual Quote

Michael Callaghan, Phiet Bui

Premium
Michael Callaghan resigned from Vermillion’s board on June 11, the company revealed in a document filed with the US Securities and Exchange Commission last week.
 
Callaghan left for personal reason and “not the result of any disagreement with the company on any matter relating to the company’s operations, policies, or practices,” Vermillion said in its document. Callaghan served on the audit and compensation committees of the board.
 

 
Miraculins said this week that company co-founder Phiet Bui is stepping down from its board and as its CSO as part of the firm’s make-over.
 
The company is moving away from proteomics research and discovery to diagnostic assay development and commercialization [See related story, this issue]. Before becoming CSO of Miraculins, Bui was president of the company.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.